American Journal of Kidney Diseases
Volume 55, Issue 6 , Pages e25-e28 , June 2010

Thrombocytopenia Associated With Use of a Biocompatible Hemodialysis Membrane: A Case Report

  • James B. Post, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to James B. Post, MD, James J. Peters VA Medical Center, 4C-12 Outpatient Renal Practice, 130 W Kingsbridge Rd, Bronx, NY 10468

Received 17 August 2009 ,Accepted 29 October 2009.

References 

  1. Craddock PR, Fehr J, Dalmasso AP, Brighan KL, Jacob HS. Hemodialysis leukopenia (Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes). J Clin Invest. 1977;59:879–888
  2. Hakim RM, Schafer AI. Hemodialysis-associated platelet activation and thrombocytopenia. Am J Med. 1985;78:575–580
  3. Chenoweth DE. Complement activation in extracorporeal circuits. Ann N Y Acad Sci. 1987;516:306–313
  4. Chenoweth DE, Henderson LW. Complement activation during hemodialysis: laboratory evaluation of hemodialyzers. Artif Organs. 1987;11:155–162
  5. Tabor B, Geissler B, Odell R, Schmidt B, Blumenstein M, Schindhelm K. Dialysis neutropenia: the role of the cytoskeleton. Kidney Int. 1998;53:783–789
  6. Lotner GZ, Lynch JM, Betz SJ, Henson PM. Human neutrophil-derived platelet activating factor. J Immunol. 1980;124:676–684
  7. Stimler NP, Bloor CM, Hugli TE, Wykle RL, McCall CE, O'Flaherty JT. Anaphylactic actions of platelet-activating factor. Am J Pathol. 1981;105:64–69
  8. Muhlfelder TW, Niemetz J, Kreutzer D, Beebe D, Ward PA, Rosenfeld SI. C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation. J Clin Invest. 1979;63:147–150
  9. Polley MJ, Nachman RL. Human platelet activation by C3a and C3a des-arg. J Exp Med. 1983;158:603–615
  10. Frank RD, Weber J, Dresbach H, Thelen H, Weiss C, Floege J. Role of contact system activation in hemodialyzer-induced thrombogenicity. Kidney Int. 2001;60:1972–1981
  11. Cotran RS, Kumar V, Collins T. Robbins Pathologic Basis of Disease. Philadelphia, PA: W.B. Saunders Co; 1999;
  12. Hoenich NA, Woffindin C, Brennan A, Cox PJ, Matthews JN, Goldfinch M. A comparison of three brands of polysulfone membranes. J Am Soc Nephrol. 1996;7:871–876
  13. Honda H, Tsukamoto I, Murasugi H, et al. Effect of polysulfone membrane dialyzers on the coagulation system. Jpn J High Performance Membr. 2005;59:77–81
  14. Taguchi N, Tsukamoto I, Yamashita Y, et al. Effects of differences in dialyzers and anticoagulant dosage on blood activation. Jpn J High Performance Membr. 2006;61:206–209
  15. Brendolan A, Nalesso F, Fortunato A, et al. Dialytic performance evaluation of Rexeed: a new polysulfone-based dialyzer with improved flow distributions. Int J Artif Organs. 2005;28:966–975

 Originally published online as doi:10.1053/j.ajkd.2009.10.059 on January 29, 2010.

PII: S0272-6386(09)01592-3

doi: 10.1053/j.ajkd.2009.10.059

American Journal of Kidney Diseases
Volume 55, Issue 6 , Pages e25-e28 , June 2010

Article Tools

* Image Usage & Resolution